Stock Taper
SCREENER COMPARE ANY 2 STOCKS
EIKN
EIKON THERAPEUTICS, INC. COMMON STOCK
NASDAQ
$10.98
▼ DOWN 4.69% (-0.54)

KEY STATISTICS

Market Cap$594.44 M
52w High$17.40
52w Low$7.90
Dividend Yield—
Frequency—
P/E-0.37
Volume239.64K
Shares Out.54.14M

COMPANY

LEADERSHIP

Roger Perlmutter
CHIEF EXECUTIVE
Roger Perlmutter

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 5, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
384

PRICE TARGET

Target High$5.00
Target Low$5.00
Target Median$5.00
Target Consensus$5.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

PRICE

$10.98 ▼ DOWN 4.69% (−$0.54)
$11.00$11.20$11.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM10.98

About Eikon Therapeutics, Inc. Common Stock

https://eikontx.com ↗

Eikon Therapeutics, founded in 2019 in Millbrae, CA, develops innovative medicines targeting unmet medical needs using a platform to characterize protein interactions, with products including immune activators and cancer-specific inhibitors.

INDUSTRY

Biotechnology

A PRODUCT EIKON THERAPEUTICS, INC. COMMON STOCK IS KNOWN FOR

EIK1001
EIK1001

EIK1001 is a TLR 7/8 dual-agonist in Phase 2/3 trials for advanced melanoma and Phase 2 for non-small cell lung cancer, designed to activate innate and adaptive immunity to treat cancer.

COMPETITORS

COMPETITOR
ACRS COMPARE
PFE COMPARE
REGN COMPARE
RLAY COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
53
LISTED HERE
11
RANKED BY POSITION SIZE
VTI
0.00% · 660.1K
XSU.TO
0.01% · 529.2K
SCHA
0.00% · 98.9K
SBIO
0.30% · 67.0K
OMFS
0.16% · 39.2K
R2SC.L
0.00% · 21.2K
XRSU.L
0.01% · 19.9K
TINY
0.97% · 11.7K
RSSL
0.01% · 10.3K
AVUS
0.00% · 6.1K
FSEG
0.00% · 23

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book3
Overall Score1

MOST RECENT ANALYST GRADES

GRADE SUMMARY
UNDERPERFORM 1
1 GRADES IN THE LAST 12 MONTHS
Wedbush UNDERPERFORM